Search

Displaying results 5071 - 5080 of 7540 in total
  1. Drug

    Tucotuzumab celmoleukin

    go.drugbank.com/drugs/DB15402
    Investigational

    Responded to Previous Treatment). … Tucotuzumab celmoleukin is under investigation in clinical trial NCT00016237 (Interleukin-2 Combined With Monoclonal Antibody Therapy in Treating Patients With Kidney, Bladder, or Lung Cancer That Has Not

  2. Drug

    N-[(2S,4S,6R)-2-(dihydroxymethyl)-4-hydroxy-3,3-dimethyl-7-oxo-4lambda~4~-thia-1-azabicyclo[3.2.0]hept-6-yl]-2-phenylacetamide

    go.drugbank.com/drugs/DB08559
    Experimental

    N-[(2S,4S,6R)-2-(dihydroxymethyl)-4-hydroxy-3,3-dimethyl-7-oxo-4lambda~4~-thia-1-azabicyclo[3.2.0]hept-6-yl]-2-phenylacetamide is a solid. This compound belongs to the penicillins. … These are organic compounds containing the penicillin core structure, which is structurally characterized by a penam ring bearing two methyl groups at position 2, and an amide group at position 6 [starting

    Synonyms: N-[(2S,4S,6R)-2-(dihydroxymethyl)-4-hydroxy-3,3-dimethyl-7-oxo-4lambda~4~-thia-1-azabicyclo[3.2.0]hept-6-yl]-2-phenylacetamide
  3. Drug

    Sodium sulfide

    go.drugbank.com/drugs/DB11159
    Approved

    However the clinical significance and mechanism of action of sodium sulfide and replication of results across other studies are not yet fully determined. … Interestingly, sodium sulfide was shown to have some cardioprotective role against cardiac ischemia or reperfusion injury, as well as protect lungs against ventilator-induced lung injury [A27275].

  4. Drug

    BB-301

    go.drugbank.com/drugs/DB17011
    Investigational

    [A260112] Developed by Benitec Biopharma, BB-301 is being investigated for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD).[L47062] … BB-301 is a modified AAV serotype 9 (AAV9) capsid expressing a unique, single bifunctional construct promoting co-expression of both codon-optimized Poly-A Binding Protein Nuclear-1 (PABPN1) and two small

  5. Drug

    LU-31130

    go.drugbank.com/drugs/DB05828
    Experimental

    LU-31130 is a rapid acting therapy developed by H. Lundbeck A/S to treat Psychosis, Schizophrenia and Schizoaffective Disorders.

  6. Drug

    anti-alpha5Beta1-integrin antibody

    go.drugbank.com/drugs/DB05870
    Experimental

    The integrin alpha5beta1 has been shown to play a critical role during angiogenesis. anti-alpha5beta1 integrin antibody inhibits angiogenesis, including vessel formation induced by vascular endothelial

  7. Drug

    Arsthinol

    go.drugbank.com/drugs/DB08928
    Experimental

    Arsthinol (INN) is an antiprotozoal agent that was first synthesized by Ernst A.H. Friedheim in 1949 via the complexing of acetarsol with 2,3-dimercaptopropanol. … Considered well tolerated when compared to other related trivalent organoarsenicals, arsthinol has even undergone recent studies as a potential anticancer agent.

  8. Drug

    1D-myo-inositol 1,4,5-trisphosphate

    go.drugbank.com/drugs/DB03401
    Experimental

    Intracellular messenger formed by the action of phospholipase C on phosphatidylinositol 4,5-bisphosphate, which is one of the phospholipids that make up the cell membrane.

  9. Drug

    Xanthine

    go.drugbank.com/drugs/DB02134
    Investigational

    It is an intermediate in the degradation of adenosine monophosphate to uric acid, being formed by oxidation of hypoxanthine.

  10. Drug

    Cilobradine

    go.drugbank.com/drugs/DB20039
    Investigational

    Cilobradine is under investigation in clinical trial NCT02264041 (Effect of Cytochrome P 450 3A4 Inhibition by Itraconazole on the Single Oral Dose Pharmacokinetics of Cilobradine).